Imirestat (AL-1576) is a potent aldose reductase inhibitor with IC50 of 8.5 nM for rat lens aldose reductase, with similar IC50 value for the human placental enzyme, shows high affinity for AKR1A1 and AKR1B1 with Ki of 47 and 46 nM respectively.

BAY1128688 is a potent, steroidal aldo-keto reductase 1C3 (AKR1C3) inhibitor with potential for endometriosis.

Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.

Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent.

Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC50 of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis.

Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats.

Myrciacetin is a flavonoid from Rhododendron dauricum. Myrciacetin is against rat lens aldose reductase with an IC50 of 13 μM.

Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.